Type 1 diabetes cases forecast to surge 30% worldwide by 2049

A study predicts a significant rise in Type 1 diabetes cases worldwide over the next two decades. According to projections, the number of individuals living with the condition is expected to increase from 9.4 million today to 12.1 million by 2049, marking a nearly 30% surge. This upward trend is not limited to the number of existing cases, as the annual incidence of new Type 1 diabetes cases is also anticipated to rise by 14% globally within the same period.

The impact of this projected increase is particularly notable in the United States, where over half a million additional people are expected to be diagnosed with Type 1 diabetes by 2049. This forecasted rise in cases is primarily attributed to genetic predispositions, environmental triggers, and heightened detection rates in wealthy nations such as the U.S., Australia, and the UK.

However, the study also highlights that the largest relative increase in Type 1 diabetes cases is anticipated to occur in low-income countries. This trend is largely due to improved accessibility to insulin and glucose monitoring, which is enhancing survival rates in these regions. Despite this, the burden of Type 1 diabetes remains predominantly among younger individuals, with those under 20 accounting for an estimated 42% of new cases last year.

Moreover, the research projects a concerning rise in all-cause deaths among people with Type 1 diabetes. All-cause mortality is expected to increase from approximately 361,000 in 2025 to 538,000 by 2049. The authors emphasize the critical need to continue enhancing access to insulin and the quality of care, especially in low-resource settings.

The findings of this study are set to be presented at a meeting of the European Association for the Study of Diabetes in Milan from September 28 to October 2. It is important to note that findings presented at medical conferences are considered preliminary until they are published in a peer-reviewed journal. The study's authors aim to underscore the urgent necessity to further improve insulin access and healthcare quality, particularly in low-income settings.